Sustained efficacy and seroconversion with the toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis B

Journal of Hepatology

Volumn 62, Issue 6, 2015, Pages 1237-1245

  Menne, Stephan ^a   Tumas, Daniel B ^b   Liu, Katherine H ^c   Thampi, Linta ^a   Aldeghaither, Dalal ^a   Baldwin, Betty H ^c   Bellezza, Christine A ^c   Cote, Paul J ^a   Zheng, Jim ^b   Halcomb, Randall ^b   Fosdick, Abigail ^b   Fletcher, Simon P ^b   Daffis, Stephane ^b   Li, Li ^b   Yue, Peng ^b   Wolfgang, Grushenka H I ^b   Tennant, Bud C ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GILEAD SCIENCES   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Immunomodulation; Seroconversion; TLR7; Woodchuck animal model

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; MESSENGER RNA; PERFORIN; PLACEBO; SUCCINATE DEHYDROGENASE; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; VIRUS DNA; [8 [3 (PYRROLIDIN 1 YLMETHYL)BENZYL] 4 AMINO 2 BUTOXY 7,8 DIHYDROPTERIDIN 6(5H) ONE; GS-9620; HEPATITIS ANTIBODY; HEPATITIS ANTIGEN; PTERIDINE DERIVATIVE; TOLL LIKE RECEPTOR 7;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC HEPATITIS B; CONTROLLED STUDY; DNA REPLICATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EMBRYO; ERYTHROCYTE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN CELL; LIVER BIOPSY; LIVER CELL CARCINOMA; LYMPHOCYTE; MALE; MAXIMUM PLASMA CONCENTRATION; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; SEROCONVERSION; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; WOODCHUCK HEPATITIS VIRUS; AGONISTS; ANIMAL; BLOOD; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEPATITIS B; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER NEOPLASMS, EXPERIMENTAL; MARMOTA; TIME FACTOR;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DNA, VIRAL; HEPATITIS ANTIBODIES; HEPATITIS ANTIGENS; HEPATITIS B; HEPATITIS B VIRUS, WOODCHUCK; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MARMOTA; PTERIDINES; SEROCONVERSION; TIME FACTORS; TOLL-LIKE RECEPTOR 7; TREATMENT OUTCOME;

EID: 84929606985     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.12.026     Document Type: Article

References (33)

1. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2004 97 107
2. H. Kwon, and A.S. Lok Hepatitis B therapy Nat Rev Gastroenterol Hepatol 8 2011 275 284
3. S. Menne, and P.J. Cote The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection World J Gastroenterol 13 2007 104 124
4. S.P. Fletcher, D.J. Chin, Y. Ji, A.L. Iniguez, B. Taillon, and D.C. Swinney Transcriptomic analysis of the woodchuck model of chronic hepatitis B Hepatology 56 2012 820 830
5. S. Akira, and K. Takeda Toll-like receptor signalling Nat Rev Immunol 4 2004 499 511
6. W. Birmachu, R.M. Gleason, B.J. Bulbulian, C.L. Riter, J.P. Vasilakos, and K.E. Lipson Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists BMC Immunol 8 2007 26
7. J.A. Hanten, J.P. Vasilakos, C.L. Riter, L. Neys, K.E. Lipson, and S.S. Alkan Comparison of human B cell activation by TLR7 and TLR9 agonists BMC Immunol 9 2008 39
8. J.Z. Oh, J.S. Kurche, M.A. Burchill, and R.M. Kedl TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway Blood 118 2011 3028 3038
9. P.A. Roethle, R.M. McFadden, H. Yang, P. Hrvatin, H. Hui, and M. Graupe Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis J Med Chem 56 2013 7324 7333
10. R.E. Lanford, B. Guerra, D. Chavez, L. Giavedoni, V.L. Hodara, and K.M. Brasky GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees Gastroenterology 144 2013 1508 1517 1517, e1501-e1510
11. U. Lopatin, G. Wolfgang, D. Tumas, C.R. Frey, C. Ohmstede, and J. Hesselgesser Safety, pharmacokinetics and pharmacodynamics of GS-9620, an oral Toll-like receptor 7 agonist Antivir Ther 18 2013 409 418
12. A. Fosdick, J. Zheng, S. Pflanz, C.R. Frey, J. Hesselgesser, and R.L. Halcomb Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses J Pharmacol Exp Ther 348 2014 96 105
13. W.E. Hornbuckle, E.S. Graham, L. Roth, B.H. Baldwin, C. Wickenden, and B.C. Tennant Laboratory assessment of hepatic injury in the woodchuck (Marmota monax) Lab Anim Sci 35 1985 376 381
14. S. Menne, S.D. Butler, A.L. George, I.A. Tochkov, Y. Zhu, and S. Xiong Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection Antimicrob Agents Chemother 52 2008 3617 3632
15. B.C. Tennant, B.H. Baldwin, L.A. Graham, M.A. Ascenzi, W.E. Hornbuckle, and P.H. Rowland Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection Hepatology 28 1998 179 191
16. S.F. Peek, P.J. Cote, J.R. Jacob, I.A. Toshkov, W.E. Hornbuckle, and B.H. Baldwin Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax) Hepatology 33 2001 254 266
17. J.R. Jacob, B.E. Korba, P.J. Cote, I. Toshkov, W.E. Delaney 4th, and J.L. Gerin Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model Antiviral Res 63 2004 115 121
18. P.J. Cote, C. Roneker, K. Cass, F. Schodel, D. Peterson, and B. Tennant New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection Viral Immunol 6 1993 161 169
19. E. Kamphuis, T. Junt, Z. Waibler, R. Forster, and U. Kalinke Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia Blood 108 2006 3253 3261
20. H. Perkins, T. Khodai, H. Mechiche, P. Colman, F. Burden, and C. Laxton Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model J Clin Immunol 32 2012 1082 1092
21. E. McKenzie, J. Sun, M. Jackson, and M.L. Gruwel Non-invasive detection of cellular proliferation in the woodchuck model of hepatocellular carcinoma Hepatology 42 2005 343A
22. B.C. Tennant, I.A. Toshkov, S.F. Peek, J.R. Jacob, S. Menne, and W.E. Hornbuckle Hepatocellular carcinoma in the woodchuck model of hepatitis B virus infection Gastroenterology 127 2004 S283 S293
23. D. Chaussabel, C. Quinn, J. Shen, P. Patel, C. Glaser, and N. Baldwin A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus Immunity 29 2008 150 164
24. M. Roggendorf, I. Schulte, Y. Xu, and M. Lu Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model J Viral Hepat 14 2007 51 57
25. J. Crettaz, I. Otano, L. Ochoa, A. Benito, A. Paneda, and I. Aurrekoetxea Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12 J Virol 83 2009 2663 2674
26. J. Liu, E. Zhang, Z. Ma, W. Wu, A. Kosinska, and X. Zhang Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection PLoS pathogens 10 2014 e1003856
27. M. Koupenova, O. Vitseva, C.R. MacKay, L.M. Beaulieu, E.J. Benjamin, and E. Mick Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis Blood 124 2014 791 802
28. Y. Wang, S. Menne, B.H. Baldwin, B.C. Tennant, J.L. Gerin, and P.J. Cote Kinetics of viremia and acute liver injury in relation to outcome of neonatal woodchuck hepatitis virus infection J Med Virol 72 2004 406 415
29. S. Wieland, R. Thimme, R.H. Purcell, and F.V. Chisari Genomic analysis of the host response to hepatitis B virus infection Proc Natl Acad Sci U S A 101 2004 6669 6674
30. C. Dunn, D. Peppa, P. Khanna, G. Nebbia, M. Jones, and N. Brendish Temporal analysis of early immune responses in patients with acute hepatitis B virus infection Gastroenterology 137 2009 1289 1300
31. K.S. Gorski, E.L. Waller, J. Bjornton-Severson, J.A. Hanten, C.L. Riter, and W.C. Kieper Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists Int Immunol 18 2006 1115 1126
32. J. Lucifora, Y. Xia, F. Reisinger, K. Zhang, D. Stadler, and X. Cheng Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA Science 343 2014 1221 1228
33. K. Rubtsova, A.V. Rubtsov, L.F. van Dyk, J.W. Kappler, and P. Marrack T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance Proc Natl Acad Sci U S A 110 2013 E3216 E3224